🔗 Share this article The Global Health Body Sounds Alert Over Critical Shortage of Obesity Medications Under one in 10 people who could benefit from weight-loss injections such as Wegovy can access them, states the World Health Organization as it releases its first guidance on the therapies. With over a billion individuals worldwide currently obese, it is calling for broader and more equitable availability to GLP-1 medication. According to projections, in excess of 2,000,000,000 will be living with obesity by 2030 without intervention. "Our new guidelines recognises that obesity is a long-term condition that can be addressed with holistic and ongoing support," stated WHO director-general Tedros Adhanom Ghebreyesus. Substantial prices, limited production capacity, and supply-chain constraints are significant hurdles to widespread availability to the treatments that can aid individuals in losing considerable body mass, says the organization. Weight-Loss Drug Supply Crisis Despite the present best projected case, the supply of such drugs could only cover about 100 million people – less than 10% of the global need, according to the health organization. The advice urges nations and manufacturers to increase availability, via approaches such as licensing agreements. The intellectual property rights on semaglutide – the primary component of a leading brand – is due to expire in a number of nations in 2026. How Weight-Loss Injections Operate GLP-1 drugs mimick a natural hormone to delay gastric emptying, curb appetite and enhance feelings of fullness so users reduce food intake. Individuals commonly start to lose weight after several weeks of commencing the once-weekly jabs. Studies points to users may put most of the weight back on after a year of stopping the drug, because their normal hunger return. To be above a healthy weight increases your likelihood for developing medical conditions, such as diabetes, cardiovascular issues, stroke, and certain cancers. Excess weight concerns people in every country and was associated with millions of fatalities worldwide in 2024, as per the WHO.
Under one in 10 people who could benefit from weight-loss injections such as Wegovy can access them, states the World Health Organization as it releases its first guidance on the therapies. With over a billion individuals worldwide currently obese, it is calling for broader and more equitable availability to GLP-1 medication. According to projections, in excess of 2,000,000,000 will be living with obesity by 2030 without intervention. "Our new guidelines recognises that obesity is a long-term condition that can be addressed with holistic and ongoing support," stated WHO director-general Tedros Adhanom Ghebreyesus. Substantial prices, limited production capacity, and supply-chain constraints are significant hurdles to widespread availability to the treatments that can aid individuals in losing considerable body mass, says the organization. Weight-Loss Drug Supply Crisis Despite the present best projected case, the supply of such drugs could only cover about 100 million people – less than 10% of the global need, according to the health organization. The advice urges nations and manufacturers to increase availability, via approaches such as licensing agreements. The intellectual property rights on semaglutide – the primary component of a leading brand – is due to expire in a number of nations in 2026. How Weight-Loss Injections Operate GLP-1 drugs mimick a natural hormone to delay gastric emptying, curb appetite and enhance feelings of fullness so users reduce food intake. Individuals commonly start to lose weight after several weeks of commencing the once-weekly jabs. Studies points to users may put most of the weight back on after a year of stopping the drug, because their normal hunger return. To be above a healthy weight increases your likelihood for developing medical conditions, such as diabetes, cardiovascular issues, stroke, and certain cancers. Excess weight concerns people in every country and was associated with millions of fatalities worldwide in 2024, as per the WHO.